JLE

Epileptic Disorders

MENU

A review of pharmacokinetic drug interactions between antimicrobial and antiseizure medications in children Volume 23, issue 2, April 2021

  • [1] Fiest K.M., Sauro K.M., Wiebe S., Patten S.B., Kwon C.-S., Dykeman J. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88:296-303.
  • [2] Zaccara G., Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16:409-431.
  • [3] Barreto M.L., Teixeira M.G., Carmo E.H. Infectious diseases epidemiology. J Epidemiol Community Health. 2006;60:192-195. 3
  • [4] Chen Z.M., Fu J.F., Shu Q., Chen Y.H., Hua C.-Z., Li F.-B. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020;16:240-246. 3
  • [5] Vissing N.H., Chawes B.L., Rasmussen M.A., Bisgaard H. Epidemiology and risk factors of infection in early childhood. Pediatrics. 2018;141:e20170933.
  • [6] Lisby S.M., Nahata M.C. Medication use and potential drug interactions in pediatric patients with infectious diseases. Hosp Pharm. 1987;22:354-356. 4
  • [7] Zaccara G., Lattanzi S. Comorbidity between epilepsy and cardiac arrhythmias: implication for treatment. Epilepsy Behav. 2019;97:304-312.
  • [8] Zaccara G., Lattanzi S., Cincotta M., Russo E. Drug treatments in patients with cardiac diseases and epilepsy. Acta Neurol Scand. 2020;142:37-49.
  • [9] Pellock J.M. Understanding co-morbidities affecting children with epilepsy. Neurology. 2004;62:S17-23. 5
  • [10] Novak P.H., Ekins-Daukes S., Simpson C.R., Mline R.M., Helms P., Mclay J.S. Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care. Br J Clin Pharmacol. 2005;59:712-717.
  • [11] Salem F., Rostami-Hodjegan A., Johnson T.N. Do children have the same vulnerability to metabolic drug-drug interactions as adults? A critical analysis of the literature. J Clin Pharmacol. 2013;53:559-566. 5
  • [12] Italiano D., Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet. 2013;52:627-645. 8
  • [13] ATC code. https://www.atccode.com/.[Accessed on February 2020].
  • [14] Medscape interaction checker. https://reference.medscape.com/drug-interactionchecker.[Accessed on May 2020].
  • [15] Liverpool Interaction COVID-19 drugs. https://www.covid19-druginteractions.org/Detailed recommendations for interactions with experimental COVID-19 antiviral therapies. https://www.covid19-druginteractions.org/prescribing-resources.[Accessed April 2020].
  • [16] Patsalos P.N., Fröscher W., Pisani F., van Rijn C.M. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002;43:365-385.
  • [17] Patsalos P.N., Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2:347-356.
  • [18] Asconapé J.J. Pharmacokinetic considerations with the use of antiepileptic drugs in patients with HIV and organ transplants. Curr Neurol Neurosci Rep. 2018;18:89. 12
  • [19] Lutz J.D., Kirby B.J., Wang L., Song Q., Ling J., Massetto B. Cytochrome P450 3A induction predicts P-glycoprotein induction; part 2: prediction of decreased substrate exposure after rifabutin or carbamazepine. Clin Pharmacol Ther. 2018;104:1191-1198.
  • [20] Patsalos P.N. Drug interactions with the newer antiepileptic drugs (AEDs)-Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin Pharmacokinet. 2013;52:1045-1061.
  • [21] Zhang C., Kwan P., Zuo Z., Baum L. The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012;64:930-942.
  • [22] Lee C.A., O’Connor M.A., Ritchie T.K., Galetin A., Cook J.A., Ragueneau-Majlessi I. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design. Drug Metab Dispos. 2015;43:490-509.
  • [23] Liu X. Transporter-mediated drug-drug interactions and their significance. Adv Exp Med Biol. 2019;1141:241-291.
  • [24] Lombardo L., Pellitteri R., Balazy M., Cardile V. Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr Neurovasc Res. 2008;5:82-92.
  • [25] Feinshtein V., Erez O., Ben-Zvi Z., Erez N., Eshkoli T., Sheizaf B. Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines. PeerJ. 2013;1:e153.
  • [26] Doyle L., Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003;22:7340-7358.
  • [27] Brivaracetam SPC. https://www.medicines.org.uk/emc/product/1963/smpc.[Accessed on April 2020].
  • [28] Salerno S.N., Burckart G.J., Huang S.M., Gonzalez D. Pediatric drug-drug interaction studies: barriers and opportunities. Clin Pharmacol Ther. 2019;105:1067-1070.
  • [29] Hines R.N. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol. 2007;21:169-175. 4
  • [30] Wen Z.P., Fan S.S., Du C., Yin T., Zhou B.-T., Peng Z.-F. Drug-drug interaction between valproic acid and meropenem: a retrospective analysis of electronic medical records from neurosurgery inpatients. J Clin Pharm Ther. 2017;42:221-227.
  • [31] Nacarkucuk E., Saglam H., Okan M. Meropenem decreases serum level of valproic acid. Pediatr Neurol. 2004;31:232-234.
  • [32] Miranda Herrero M.C., Alcaraz Romero A.J., Escudero Vilaplana V., Lafever S.N.F., Fernandez-Llamazares C.M., Valderrama E.B. Pharmacological interaction between valproic acid and carbapenem: what about levels in pediatrics? Eur J Paediatr Neurol. 2015;19:155-161.
  • [33] Suzuki E., Koyama K., Nakai D. Goda R,Kuga H, Chiba K Observation of clinically relevant drug interaction in chimeric mice with humanized livers: the case of valproic acid and carbapenem antibiotics. Eur J Drug Metab Pharmacokinet. 2017;42:965-972. .
  • [34] Suzuki E., Nakai D., Ikenaga H., Fusegawa K., Goda R., Kobayashi N. inhibition of acylpeptide hydrolase by carbapenem antibiotics causes the decrease of plasma concentration of valproic acid in dogs. Xenobiotica. 2016;46:126-131. In vivo
  • [35] Wu C.C., Pai T.Y., Hsiao F.Y., Shen Li-Jiuan, Lin Wu Fe-Lin. The effect of different carbapenem antibiotics (ertapenem, imipenem/cilastatin, and meropenem) on serum valproic acid concentrations. Ther Drug Monit. 2016;38:587-592.
  • [36] Wang J.S., Backman J.T., Kivistö K.T., Neuvonen P.J. Effects of metronidazole on midazolam metabolism and . Eur J Clin Pharmacol. 2000;56:555-559. in vitroin vivo
  • [37] Krasinski K., Kusmiesz H., Nelson J.D. Pharmacologic interactions among chloramphenicol, phenytoin and phenobarbital. Pediatr Infect Dis. 1982;1:232-235.
  • [38] Campbell C.L. Primidone intoxication associated with concurrent use of chloramphenicol. J Am Vet Med Assoc. 1983;182:992-993.
  • [39] van Wieringen A., Vrijlandt C.M. Ethosuximide intoxication caused by interaction with isoniazid. Neurology. 1983;33:1227-1228.
  • [40] Sigaroudi A., Kullak-Ublick G.A., Weiler S. Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine. Eur J Clin Pharmacol. 2016;72:377-378.
  • [41] Santucci R., Fothergill H., Laugel V., Perville A., De Saint Martin A., Gerout A.-C. The onset of acute oxcarbazepine toxicity related to prescription of clarithromycin in a child with refractory epilepsy. Br J Clin Pharmacol. 2010;69:314-316.
  • [42] Rojas Sánchez P., Domínguez S., Jiménez De Ory S., Prieto L., Rojo P., Mellado P. Trends in drug resistance prevalence, HIV-1 variants and clinical status in HIV-1-infected pediatric population in Madrid: 1993 to 2015 Analysis. Pediatr Infect Dis J. 2018;37:e48-57.
  • [43] Streatfield P.K., Khan W.A., Bhuiya A., Hanifi S.M.A., Alam N., Millogo O. HIV/AIDS-related mortality in Africa and Asia: evidence from INDEPTH health and demographic surveillance system sites. Glob Health Action. 2014;7:25370.
  • [44] Birbeck G.L., French J.A., Perucca E., Simpson D.M., Fraimow H., George J.M. Antiepileptic drug selection for people with HIV/AIDS: Evidence-based guidelines from the ILAE and AAN. Epilepsia. 2012;53:207-214.
  • [45] Cobicistat SPC. https://www.medicines.org.uk/emc/product/3466/smpc.[Accessed May 2020].
  • [46] Ritonavir SPC. https://www.medicines.org.uk/emc/product/221.[Accessed May 2020].
  • [47] Lim M.L., Min S.S., Eron J.J., Bertz R.J., Robinson M., Gaedigk A. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr. 2004;36:1034-1040.
  • [48] Cattaneo D., Baldelli S., Cozzi V., Fusi M., Atzori C., Michel V. Drug-drug interactions between antiretrovirals and carbamazepine/oxcarbazepine: a real-life investigation. Ther Drug Monit. 2020;42:330-334.
  • [49] Kandil M.M., Badowski M.E., Schriever C.A. Sustained viral suppression with co-administration of oxcarbazepine and dolutegravir. Int J STD AIDS. 2018;29:831-833.
  • [50] Palazzo A., Trunfio M., Pirriatore V., Milesi M., De Nicolo A., Alcantarini C. Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. J Antimicrob Chemother. 2018;73:826-827.
  • [51] DiCenzo R., Peterson D., Cruttenden K., Morse G., Riggs G., Gelbard H. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004;48:4328-4331.
  • [52] van der Lee M.J., Dawood L., ter Hofstede H.J., de Graaff-Teulen M.J.A., van Ewijk-Beneken Kolmer E.W.J., Caliskan-Yassen Nurcan. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2006;80:159-168.
  • [53] Burger D.M., Huisman A., Van Ewijk N., Neisingh H., Uden Van P., Rongen G.A. The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe. Clin Pharmacol Ther. 2008;84:698-703.
  • [54] Naccarato M., Yoong D., Kovacs C., Gough K. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antivir Ther. 2012;17:589-592.
  • [55] Goicoechea M, Best B, Capparelli E, Haubrich R; California Collaborative Treatment Group. Concurrent use of efavirenz and oxcarbazepine may not affect efavirenz plasma concentrations. Clin Infect Dis 2006; 43:116-7.
  • [56] Clemente M.G., Antonucci R., Sotgiu G., Dettori M., Piana A., Vajiro P. Present and future management of viral hepatitis B and C in children. Clin Res Hepatol Gastroenterol. 2020;44:801-809. 6
  • [57] Granot E., Sokal E.M. Hepatitis C virus in children: deferring treatment in expectation of direct-acting antiviral agents. Isr Med Assoc J. 2015;17:707-711.
  • [58] Garrison K.L., German P., Mogalian E., Mathias A. The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection. Drug Metab Dispos. 2018;46:1212-1225.
  • [59] Li H., Yan L., Shi Y., Shang Jin L.V.D., Bai Lang. Hepatitis B virus infection: overview. Adv Exp Med Biol. 2020;1179:1-16.
  • [60] Shen K., Yang Y., Wang T., Zhao D., Jiang Y., Jin R. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World J Pediatr. 2020;16:223-231. 3
  • [61] Zaccara G., Gualdani E., Policardo L., Palumbo P., Francesconi P. Frequency of drug combinations between enzyme-inducing first-generation antiepileptic drugs and inducible drugs in patients with epilepsy. Epilepsy Behav. 2018;87:92-95.
  • [62] Acton E.K., Willis A.W., Gelfand M.A., Kasner S.E. Poor concordance among drug compendia for proposed interactions between enzyme-inducing antiepileptic drugs and direct oral anticoagulants. Pharmacoepidemiol Drug Saf. 2019;28:1534-1538.
  • [63] Okulicz J.F., Grandits G.A., French J.A., Perucca E., George J.M., Landrum M.L. The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study. Epilepsy Res. 2013;103:245-253.
  • [64] Okulicz J.F., Grandits G.A., French J.A., George J.M., Simpson D.M., Birbeck G.L. Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study. AIDS Res Ther. 2011;8:18.
  • [65] Sheehan N.L., Brouillette M.J., Delisle M.S., Allan J. Possible interaction between lopinavir/ritonavir and valproic Acid exacerbates bipolar disorder. Ann Pharmacother. 2006;40:147-150. 1
  • [66] Wong Y.Y., Ludden T.M., Bell R.D. Effect of erythromycin on carbamazepine kinetics. Clin Pharmacol Ther. 1983;33:460-464. 4
  • [67] Albani F., Riva R., Baruzzi A. Clarithromycin-carbamazepine interaction: a case report. Epilepsia. 1993;34:161-162. 1
  • [68] Al-Quteimat O., Laila A. Valproate interaction with carbapenems: review and recommendations. Hosp Pharm. 2020;55:181-187. 3
  • [69] Purkins L., Wood N., Ghahramani P., Love E.R., Eve M.D., Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol. 2003;56:37-44. 1
  • [70] Tian D.D., Leonowens C., Cox E.J., Gonzalez-Pérez V., Frederick K.S., Scarlett Y.V. Indinavir increases midazolam N-glucuronidation in humans: identification of an alternate CYP3A inhibitor using an to approach. Drug Metab Dispos. 2019;47:724-731. in vitroin vivo
  • [71] RxList. https://www.rxlist.com/drug-interaction-checker.htm.[Accessed on May 2020].
  • [72] Liverpool Interaction checker. https://www.hiv-druginteractions.org/.[Accessed April 2020].
  • [73] Patsalos P.N., Berry D.J., Bourgeois B.F., Cloyd J.C., Glauser T.A., Johannessen S.I. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239-1276. 7